AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29604316 — intervention group
Group type: COMPARATOR
Intervention: 0% F placebo toothpaste
Number of subjects: 0
Study 26914406 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 140 mg
Number of subjects: 661
Study 26914406 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodalumab 210 mg
Number of subjects: 661
Study 26914406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 661
Study 25431880 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish (Atlantic salmon three times per week from September to February)
Number of subjects: 95
Study 25431880 — intervention group
Group type: COMPARATOR
Intervention: Control (alternative meal, e.g., chicken, pork, or beef three times per week during the same period)
Number of subjects: 95
Study 22260297 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine 1.5 mg/kg followed by a continuous infusion of 2 mg/kg/h
Number of subjects: 52
Study 22260297 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline (control)
Number of subjects: 52
Study 19801174 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no screening)
Number of subjects: 15822
Study 17352868 — intervention group
Group type: EXPERIMENTAL
Intervention: Chaige Qingre Granule (6 g, 4 times daily for 3 days)
Number of subjects: 172
Study 17352868 — intervention group
Group type: COMPARATOR
Intervention: Fufang Shuanghua Granule (6 g, 4 times daily for 3 days)
Number of subjects: 172
Study 15655204 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication with simple sutured crural closure (n = 50)
Number of subjects: 100
Study 15655204 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Nissen fundoplication with prosthetic hiatal closure (n = 50)
Number of subjects: 100
Study 12885350 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with 10(7) or 10(8) irradiated CD80-modified tumor cells with GM-CSF or BCG, three times at 2-week intervals and then monthly until progressive disease developed.
Number of subjects: 30
Study 12885350 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with 10(8) tumor cell dose.
Number of subjects: 30
Study 10534821 — intervention group
Group type: EXPERIMENTAL
Intervention: Teledermatology consultation
Number of subjects: 197
Study 10534821 — intervention group
Group type: COMPARATOR
Intervention: Hospital consultation
Number of subjects: 197
Study 9346678 — intervention group
Group type: EXPERIMENTAL
Intervention: ganciclovir (6 mg/kg/day intravenously for a total of 100 days)
Number of subjects: 26
Study 9346678 — intervention group
Group type: COMPARATOR
Intervention: acyclovir (10 mg/kg every 8 hours intravenously until discharged and then 800 mg orally every 6 hours for a total of 100 days)
Number of subjects: 26
Study 9346678 — intervention group
Group type: EXPERIMENTAL
Intervention: ganciclovir
Number of subjects: 26
Study 9346678 — intervention group
Group type: COMPARATOR
Intervention: acyclovir
Number of subjects: 26
Study 1768538 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine with adrenaline 1:200,000
Number of subjects: 20
Study 1768538 — intervention group
Group type: COMPARATOR
Intervention: 2% lignocaine
Number of subjects: 20
Study 7150406 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised bicycle ergometer exercise for 2 months followed by 2 months of unsupervised training
Number of subjects: 59
Study 7150406 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 59
Study 7150406 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised bicycle ergometer exercise
Number of subjects: 59
Study 30382352 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotiv 250 (250 mg of H. perforatum)
Number of subjects: 82
Study 30382352 — intervention group
Group type: EXPERIMENTAL
Intervention: Remotiv 500 (500 mg of H. perforatum)
Number of subjects: 82
Study 30382352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 28217975 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 110
Study 28217975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 26358764 — intervention group
Group type: COMPARATOR
Intervention: Topical combination of calcipotriol and betamethasone (Group A)
Number of subjects: 44
Study 26358764 — intervention group
Group type: EXPERIMENTAL
Intervention: Monochromatic excimer light (MEL) (Group B)
Number of subjects: 44
Study 26358764 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 44
Study 24138555 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-HD day with one meal served at baseline (NHDM1)
Number of subjects: 12
Study 24138555 — intervention group
Group type: EXPERIMENTAL
Intervention: HD day with one meal served during HD (HDM1)
Number of subjects: 12
Study 24138555 — intervention group
Group type: EXPERIMENTAL
Intervention: HD day with two meals served during and after HD (HDM2)
Number of subjects: 12
Study 24138555 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (session 1)
Number of subjects: 12
Study 22946500 — intervention group
Group type: EXPERIMENTAL
Intervention: DCR with both anterior and posterior flap anastomosis (Group 1)
Number of subjects: 164
Study 22946500 — intervention group
Group type: COMPARATOR
Intervention: DCR with only anterior flap anastomosis (Group 2)
Number of subjects: 164
Study 18574489 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular passive movements administered for 10 min, 10 times a week for 6 months.
Number of subjects: 20
Study 18574489 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated ankles).
Number of subjects: 20
Study 18574489 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (passive movements).
Number of subjects: 20
Study 17959531 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion tensor magnetic resonance imaging (DTI)
Number of subjects: 45
Study 10768528 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-related circuit training (experimental group)
Number of subjects: 12
Study 10768528 — intervention group
Group type: COMPARATOR
Intervention: Upper-limb tasks (control group)
Number of subjects: 12
Study 8633581 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (500 mg/day)
Number of subjects: 40
Study 8633581 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (3 g/day)
Number of subjects: 40
Study 1480364 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar anesthesia (LA)
Number of subjects: 95
Study 1480364 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 95
Study 3881558 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine treatment
Number of subjects: 0
Study 3881558 — intervention group
Group type: COMPARATOR
Intervention: Gradual methadone reduction
Number of subjects: 0
Study 30412655 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg or 25 mg
Number of subjects: 1517
Study 29326330 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention including individualised care/action plans and telephone consults (12-weekly then 9-monthly)
Number of subjects: 470
Study 29326330 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 470
Study 27279511 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block using 20 mL 0.25% bupivacaine
Number of subjects: 34
Study 27279511 — intervention group
Group type: COMPARATOR
Intervention: Control block using 20 mL 0.9% Sodium chloride
Number of subjects: 34
Study 24667487 — intervention group
Group type: EXPERIMENTAL
Intervention: levomilnacipran extended-release (ER)
Number of subjects: 0
Study 24667487 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 22964983 — intervention group
Group type: EXPERIMENTAL
Intervention: Maoto+oseltamivir (group 3)
Number of subjects: 150
Study 22964983 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanamivir (group 4)
Number of subjects: 150
Study 22964983 — intervention group
Group type: EXPERIMENTAL
Intervention: Maoto (group 1)
Number of subjects: 150
Study 22964983 — intervention group
Group type: COMPARATOR
Intervention: Control (oseltamivir, group 2)
Number of subjects: 150
Study 19578163 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin therapy (40 mg/day)
Number of subjects: 480
Study 18062391 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized Purell Instant Hand Sanitizer regimen, education, reinforcement
Number of subjects: 2
Study 18062391 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized Purell Instant Hand Sanitizer regimen
Number of subjects: 2
Study 18062391 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2
Study 16173357 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy
Number of subjects: 0
Study 16173357 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma Model Therapy
Number of subjects: 0
Study 12666888 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide
Number of subjects: 59
Study 12666888 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% carbamide peroxide
Number of subjects: 59
Study 12666888 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% carbamide peroxide
Number of subjects: 59
Study 12666888 — intervention group
Group type: EXPERIMENTAL
Intervention: 10%, 15%, and 20% carbamide peroxide
Number of subjects: 59
Study 9885787 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-4 injection during the follicular phase
Number of subjects: 39
Study 9885787 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-4 injection during the luteal phase
Number of subjects: 39
Study 9885787 — intervention group
Group type: COMPARATOR
Intervention: CCK-4 injection (both phases)
Number of subjects: 39
Study 7726308 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate infusion with 0.9% sodium chloride
Number of subjects: 34
Study 7726308 — intervention group
Group type: COMPARATOR
Intervention: Lactate infusion with 5% dextrose in water
Number of subjects: 34
Study 7726308 — intervention group
Group type: EXPERIMENTAL
Intervention: Both infusions
Number of subjects: 34
Study 2174121 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-571 (160 mg)
Number of subjects: 12
Study 2174121 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30992301 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixazomib in combination with MEC (mitoxantrone, etoposide, cytarabine)
Number of subjects: 0
Study 30992301 — intervention group
Group type: COMPARATOR
Intervention: MEC (mitoxantrone, etoposide, cytarabine) alone
Number of subjects: 0
Study 28033159 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mL of 0.4% dexamethasone)
Number of subjects: 40
Study 28033159 — intervention group
Group type: COMPARATOR
Intervention: Control (1 mL of saline)
Number of subjects: 40
Study 28033159 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 40
Study 28033159 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 25450293 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin treatment in cultured endometrial cells (Ishikawa cells)
Number of subjects: 12
Study 25450293 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum leptin levels in overweight/obese PCOS patients
Number of subjects: 12
Study 25450293 — intervention group
Group type: COMPARATOR
Intervention: Control group (12 control women)
Number of subjects: 12
Study 23932008 — intervention group
Group type: EXPERIMENTAL
Intervention: Casual or unexpected partners
Number of subjects: 1469
Study 23932008 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners drinking alcohol 2 hours prior to sex
Number of subjects: 1469
Study 23932008 — intervention group
Group type: EXPERIMENTAL
Intervention: >=3 years age discordant partners
Number of subjects: 1469
Study 23932008 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners met in public places
Number of subjects: 1469
Study 22263401 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 30
Study 22263401 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 30
Study 19923847 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-interval dosing (triptorelin 3.75 mg by intramuscular injection every 6 weeks for a total of 4 doses)
Number of subjects: 70
Study 19923847 — intervention group
Group type: COMPARATOR
Intervention: Conventional dosing (1 injection every 4 weeks for a total of 6 doses)
Number of subjects: 70
Study 17427818 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching, self-priming dentin bonding agent
Number of subjects: 76
Study 17427818 — intervention group
Group type: COMPARATOR
Intervention: Self-priming resin requiring a separate etch step
Number of subjects: 76
Study 16163749 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine and Nortriptyline
Number of subjects: 248
Study 16163749 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 248
Study 11967670 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic surgery (HALS)
Number of subjects: 54
Study 11967670 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic surgery (LS)
Number of subjects: 54
Study 9475525 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Number of subjects: 48
Study 9475525 — intervention group
Group type: COMPARATOR
Intervention: No photodynamic therapy
Number of subjects: 48
Study 9475525 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 48
Study 7620004 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin (4 g) three times daily for up to 7 days
Number of subjects: 82
Study 7620004 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times daily for up to 7 days
Number of subjects: 82
Study 7620004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 2244441 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine-epinephrine mixture (0.5% bupivacaine, 5 micrograms/ml epinephrine)
Number of subjects: 32
Study 2244441 — intervention group
Group type: COMPARATOR
Intervention: Plain bupivacaine
Number of subjects: 32
Study 420388 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile cast brace
Number of subjects: 16
Study 420388 — intervention group
Group type: COMPARATOR
Intervention: Standard cylinder cast
Number of subjects: 16
Study 31332549 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation plus routine antihistamine medication (cetirizine)
Number of subjects: 80
Study 31332549 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine plus placebo
Number of subjects: 80
Study 29258261 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose (Orafti® P95) at 15 g/day
Number of subjects: 97
Study 29258261 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose (Orafti® P95) at 10 g/day
Number of subjects: 97
Study 29258261 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 97
Study 25421343 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive training (15-min circle training, 5 times per week for 12 weeks)
Number of subjects: 28
Study 22858513 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 96
Study 22858513 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 96
Study 21715514 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (2000 IU once daily)
Number of subjects: 92
Study 18953578 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Training (PT)
Number of subjects: 147
Study 18953578 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Training plus Cognitive-Behavioral Therapy (PT + CBT)
Number of subjects: 147
Study 16972160 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D Index score
Number of subjects: 221
Study 16972160 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D Index and Visual Analogue scores
Number of subjects: 221
Study 16972160 — intervention group
Group type: COMPARATOR
Intervention: EQ-5D scores
Number of subjects: 221
Study 15804802 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg/d
Number of subjects: 1000
Study 15804802 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg/d
Number of subjects: 1000
Study 11190013 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac 0.1% ophthalmic solution
Number of subjects: 120
Study 11190013 — intervention group
Group type: COMPARATOR
Intervention: ketorolac 0.5% ophthalmic solution
Number of subjects: 120
Study 10073029 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved passing peritoneum extraperitoneal cesarean section
Number of subjects: 150
Study 10073029 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraperitoneal cesarean section
Number of subjects: 150
Study 10073029 — intervention group
Group type: EXPERIMENTAL
Intervention: Low segment cesarean section
Number of subjects: 150
Study 10073029 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 150
Study 8104727 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg.kg‐1
Number of subjects: 0
Study 8104727 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 0.08 mg.kg‐1
Number of subjects: 0
Study 2947953 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms hepatitis B vaccine
Number of subjects: 662
Study 2947953 — intervention group
Group type: COMPARATOR
Intervention: 10 micrograms hepatitis B vaccine
Number of subjects: 662
Study 29463591 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Advice Group (dietary and lifestyle advice through three face-to-face sessions and three telephone calls)
Number of subjects: 624
Study 29463591 — intervention group
Group type: COMPARATOR
Intervention: Standard Care Group (routine antenatal care)
Number of subjects: 624
Study 26821959 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-loaded single-row repair augmented with platelet-rich plasma fibrin membrane
Number of subjects: 40
Study 26821959 — intervention group
Group type: COMPARATOR
Intervention: Suture-bridging double-row repair augmented with platelet-rich plasma fibrin membrane
Number of subjects: 40
Study 26821959 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (triple-loaded single-row and suture-bridging double-row)
Number of subjects: 40
Study 24927068 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical agent (Skinceuticals Body Tightening Concentrate) applied twice daily to one designated thigh/buttock
Number of subjects: 20
Study 24927068 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency (RF) device (Alma Accent) treatment
Number of subjects: 20
Study 24927068 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical agent (Skinceuticals Body Tightening Concentrate)
Number of subjects: 20
Study 22345330 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-based cornstarch porridge fortified with 10 mg elemental iron (FeSO4), daily, during 14 weeks
Number of subjects: 131
Study 22345330 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 131
Study 20079569 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow breathing
Number of subjects: 52
Study 20079569 — intervention group
Group type: COMPARATOR
Intervention: Normal breathing
Number of subjects: 52
Study 18755342 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) or enoxaparin plus a glycoprotein (GP) IIb/IIIa inhibitor
Number of subjects: 7789
Study 18755342 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin plus a GP IIb/IIIa inhibitor
Number of subjects: 7789
Study 18755342 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 7789
Study 16381363 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-point laparoscopic ovarian electrocauterization
Number of subjects: 187
Study 16381363 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-point laparoscopic ovarian electrocauterization
Number of subjects: 187
Study 16381363 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-point laparoscopic ovarian electrocauterization
Number of subjects: 187
Study 12063455 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic systemic perfusion (37 degrees C)
Number of subjects: 113
Study 12063455 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic systemic perfusion (26 degrees C)
Number of subjects: 113
Study 10102851 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention for breathlessness (breathing control, activity pacing, relaxation techniques, psychosocial support)
Number of subjects: 119
Study 10102851 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (standard management and treatment for breathlessness, breathing assessments)
Number of subjects: 119
Study 8582466 — intervention group
Group type: COMPARATOR
Intervention: HFA-Placebo
Number of subjects: 12
Study 8582466 — intervention group
Group type: COMPARATOR
Intervention: CFC-Placebo
Number of subjects: 12
Study 8582466 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-Salbutamol
Number of subjects: 12
Study 2236367 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional pulsating fluorescent light
Number of subjects: 48
Study 2236367 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluorescent light
Number of subjects: 48
Study 2236367 — intervention group
Group type: COMPARATOR
Intervention: Steady fluorescent light
Number of subjects: 48
Study 2236367 — intervention group
Group type: COMPARATOR
Intervention: Incandescent light
Number of subjects: 48
Study 568293 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (N-acetyl-p-amino-phenol)
Number of subjects: 10
Study 568293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30183710 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based stress management program ('I'm managing my stress'), composed of four sessions based on cognitive-behavioral therapy.
Number of subjects: 128
Study 30183710 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 128
Study 27732819 — intervention group
Group type: EXPERIMENTAL
Intervention: Current standard of care plus ZMapp (50 mg/kg, administered every third day)
Number of subjects: 72
Study 27732819 — intervention group
Group type: COMPARATOR
Intervention: Current standard of care alone
Number of subjects: 72
Study 24768960 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision
Number of subjects: 0